JP2005538190A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538190A5
JP2005538190A5 JP2005505626A JP2005505626A JP2005538190A5 JP 2005538190 A5 JP2005538190 A5 JP 2005538190A5 JP 2005505626 A JP2005505626 A JP 2005505626A JP 2005505626 A JP2005505626 A JP 2005505626A JP 2005538190 A5 JP2005538190 A5 JP 2005538190A5
Authority
JP
Japan
Prior art keywords
administered
composition
receptor agonist
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005505626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/023511 external-priority patent/WO2004011010A1/en
Publication of JP2005538190A publication Critical patent/JP2005538190A/ja
Publication of JP2005538190A5 publication Critical patent/JP2005538190A5/ja
Pending legal-status Critical Current

Links

JP2005505626A 2002-07-29 2003-07-29 心筋潅流イメージング Pending JP2005538190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39917602P 2002-07-29 2002-07-29
US39917702P 2002-07-29 2002-07-29
US42690202P 2002-11-15 2002-11-15
US45980303P 2003-04-02 2003-04-02
PCT/US2003/023511 WO2004011010A1 (en) 2002-07-29 2003-07-29 Myocardial perfusion imaging using a2a receptor agonists

Publications (2)

Publication Number Publication Date
JP2005538190A JP2005538190A (ja) 2005-12-15
JP2005538190A5 true JP2005538190A5 (enExample) 2006-08-10

Family

ID=31192376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005505626A Pending JP2005538190A (ja) 2002-07-29 2003-07-29 心筋潅流イメージング

Country Status (12)

Country Link
US (2) US7683037B2 (enExample)
EP (1) EP1524984A1 (enExample)
JP (1) JP2005538190A (enExample)
KR (1) KR20050026546A (enExample)
CN (1) CN1671399A (enExample)
AU (1) AU2003259264A1 (enExample)
CA (1) CA2492855C (enExample)
IL (1) IL166555A0 (enExample)
MX (1) MXPA05001123A (enExample)
NO (1) NO20051059L (enExample)
NZ (1) NZ537975A (enExample)
WO (1) WO2004011010A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
NZ537975A (en) 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2005013801A2 (en) * 2003-07-18 2005-02-17 Munn Charles S Enhanced cardiac radionuclide imaging techniques
PT2366396E (pt) * 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
AU2005295437B2 (en) * 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
MX2008016254A (es) * 2006-06-22 2009-01-15 Cv Therapeutics Inc Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (ko) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
US11730430B2 (en) * 2012-09-21 2023-08-22 The General Hospital Corporation System and method for single-scan rest-stress cardiac pet
WO2014063134A1 (en) 2012-10-19 2014-04-24 New York University Methods for inhibiting osteolysis
WO2014083580A2 (en) * 2012-11-30 2014-06-05 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
CN105997852B (zh) * 2016-05-15 2018-10-09 南京海融医药科技股份有限公司 一种瑞加诺生注射液及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4089959A (en) 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
SE7810946L (sv) 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 2−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE68916036T2 (de) 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
US5283327A (en) 1989-06-20 1994-02-01 Yamasa Shoyu Kabushiki Kaisha Tri-O-acetyl-2-alkynyladenosines
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状2‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 2‐アルキニルアデノシン誘導体
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
EP0644935A1 (en) 1992-06-12 1995-03-29 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
CA2112031A1 (en) 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5703085A (en) 1994-02-23 1997-12-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5704491A (en) 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
WO1998052611A1 (en) 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
WO1998057651A1 (en) 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
EP1011608A4 (en) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7109203B2 (en) 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
CN100467469C (zh) 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002366811B2 (en) 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
PT2366396E (pt) 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
NZ554485A (en) 2004-10-15 2010-12-24 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
AU2005295437B2 (en) 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
WO2006076698A1 (en) 2005-01-12 2006-07-20 King Pharmaceuticals Reserch & Development, Inc. Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
MX2008016254A (es) 2006-06-22 2009-01-15 Cv Therapeutics Inc Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia.
US20090081120A1 (en) 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (ko) 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
WO2008042796A2 (en) 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
JP2010515081A (ja) 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
RU2011115815A (ru) 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии

Similar Documents

Publication Publication Date Title
JP2005538190A5 (enExample)
Tapson et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial
US20100086483A1 (en) Method of multidetector computed tomagraphy
JP2010502649A5 (enExample)
JP2020033360A5 (enExample)
Ahad et al. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies
JP2010515081A5 (enExample)
CA2492855A1 (en) Myocardial perfusion imaging using a2a receptor agonists
RU2009106862A (ru) Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
RU2007114908A (ru) Применение агонистов аденозиновых рецепторов a2a
JP2010526837A5 (enExample)
WO2013118773A1 (ja) 特発性炎症性筋疾患の予防又は治療剤
Mehta et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
US20120014912A1 (en) Palatable pharmaceutical composition
Schor et al. Susadrin transmucosal tablets (nitroglycerin in Synchron® controlled-release base)
Platts et al. Midodrine prescribed to improve recurrent post-spaceflight orthostatic hypotension
JP2007504268A5 (enExample)
McManus et al. Antifungal drugs
CN117940128A (zh) 异丁司特用于防止眼癌转移
JP2007501806A5 (enExample)
CN105920586A (zh) 干扰素的雾化吸入剂
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
JP2019533672A5 (enExample)
CN105816857A (zh) 干扰素的水溶液制剂
CN112190708B (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用